Polycystic Ovary Syndrome (PCOS)
Conditions
Interventions
Group A:LE group. Letrozole is taken orally on the 3-5 day of the menstrual cycle.
Group B:LE+Gn group. Letrozole is taken orally on the 3-5 day of the menstrual cycle, and gonadotropin is intramuscularly injected.
Group C:CC group, Clomiphene citrate, CC is taken orally on the 3-5 day of the menstrual cycle.
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Woman with PCOS meeting the 2003 Rotterdam diagnostic criteria; 2.Age less than 40 years old, normal sex life, infertility course for more than 1 year; 3.hysterosalpingography indicated that the uterine morphology was normal, and at least one side of the fallopian tube was unobstructed; 4.There was no abnormal or mild oligospermia or asthenospermia in the sperm analysis results of the spouses; 5.all organs function normally, without any endocrine disorders, such as hypophysis, hyperthyroidism; 6.Before the trial, they have understood in detail the nature, significance, possible benefits and potential dangers of the trial, and have voluntarily participated in the clinical trial, communicated well with the investigator, complied with the requirements of the entire study, and have signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Diseases with abnormal clinical manifestations to be excluded, including, but not limited to, neurological, cardiovascular, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal systemic disorders that, in the opinion of the Investigator, may affect the outcome or safety of the subject's participation in the study; 2.Clinical evidence of diseases that need to be excluded upon inquiry, including but not limited to neurological, cardiovascular, hematological and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal system diseases, and the researcher believes that these diseases may affect the subject's participation in the study results or safety; 3.Patients with suspected or confirmed pregnancy; patients breastfeeding within six months; 4.Participation in other drug clinical trials within the past 3 months; 5.Diseases with abnormal clinical manifestations to be excluded, including, but not limited to, neurological, cardiovascular, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, respiratory, metabolic, and skeletal systemic disorders that, in the opinion of the Investigator, may affect the outcome or safety of the subject's participation in the study; 6.History of uterine or uterine cavity abnormal diseases; 7.Previous exposure to teratogenic substances, radiation, etc; 8.Patients with relevant drug contraindications: e.g., history of breast cancer, history of venous thrombosis, history of migraine, history of severe liver disease; 9.Subjects who the researcher believes have poor compliance or any factors that are not suitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ovulation rate;Clinical pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of antral follicles;Number of mature follicles;Endometrial thickness;The level of progesterone;The level of estradiol;The level of luteinizing hormone;The rate of OHSS;Cumulative pregnancy rate;Ongoing pregnancy rate;Biochemical pregnancy rate;Pregnancy loss rate;Early abortion rate;live birth rate;Ectopic pregnancy rate;Mutiple pregnancy rate; | — |
Countries
China
Contacts
Public ContactMa Lin
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed